进展性脑梗死患者应用依达拉奉及低分子肝素治疗的效果观察  

Effect of Edaravone and Low Molecular Weight Heparin on Patients with Progressive Cerebral Infarction

作　　者：祁恒旭[1] 张芸[2] 陈忠军[1] 范铁平[1] 赵旭生[1] 李迪[1] QI Heng-xu;ZHANG Yun;CHEN Zhong-jun;FAN Tie-ping;ZHAO Xu-sheng;LI Di(Department of Neurology, Dalian Central Hospital, Dalian 116000, China;Critical Care Medcine Three Wards, Dalian Central Hospital, Dalian 116000, China)

机构地区：[1]大连市中心医院神经介入科,辽宁大连116033 [2]大连市中心医院重症医学科三病房,辽宁大连116033

出　　处：《中国医药指南》2019年第22期20-21,共2页Guide of China Medicine

摘　　要：目的观察进展期脑梗死患者应用依达拉奉及低分子肝素治疗的临床疗效。方法选取自2017年1月至2018年1月于我院收治的进展性脑梗死患者60例,采用信封法随机分为试验组和对照组,对照组30例,采用低分子肝素,试验组30例,在对照组基础上联合依达拉奉,应用NIHSS量表观察两组患者的临床疗效。结果试验组优于对照组,有统计学差异(P<0.05)。结论依达拉奉及低分子肝素治疗进展性脑梗死患者安全有效,值得推广。Objective To observe the clinical efficacy of Edaravone and low molecular weight heparin in patients with progressive cerebral infarction. Methods 60 patients with progressive cerebral infarction treated in our hospital from January 2017 to January 2018 were randomly divided into the experimental group and the control group. The control group was divided into the control group and the control group. 30 cases in the control group were treated with low molecular weight heparin (LMWH) and 30 cases in the experimental group. On the basis of the control group, edaravone was combined with the NIHSS scale to observe the clinical efficacy of the two groups. Results The experimental group was better than the control group, with statistical difference (P<0.05). Conclusion Edaravone and low molecular weight heparin are effective and safe in the treatment of progressive cerebral infarction.

关 键 词：依达拉奉 低分子肝素 进展性脑梗死 

分 类 号：R743.34[医药卫生—神经病学与精神病学]